Carcinogenesis, Vol. 23, No. 12, 2103-2109,
December 2002
© 2002 Oxford University Press
CARCINOGENESIS |
Vitamin D3 receptor ablation sensitizes skin to chemically induced tumorigenesis
1 Department of Biology, University of Notre Dame, Notre Dame, IN 46556, USA and
2 The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609-1500, USA
1,25-Dihydroxyvitamin D3 (1,25D3) is the biologically active form of vitamin D3 that interacts with the nuclear vitamin D3 receptor (VDR) to modulate gene expression in a tissue-specific fashion. 1,25D3 is a potent regulator of cell proliferation, differentiation and apoptosis in a variety of cell types, including keratinocytes. In these studies, we assessed the sensitivity of mice homozygous for a null allele of the VDR (VDR-/- mice) and their wild-type counterparts (VDR+/+ mice) to oral administration of the carcinogen 7,12-dimethylbenzanthracene (DMBA). Although the protocol was optimized for the induction of mammary tumors, 85% of VDR-/- mice developed persistent skin tumors within 60 days of carcinogen exposure. In VDR-/- mice exposed to DMBA, papillomas arose on all areas of the body, with an average tumor burden of 5.3 papillomas/mouse. No papillomas or any other skin lesions were observed in age- and sex-matched VDR+/+ mice dosed with DMBA and followed for 6 months. The majority (80%) of skin tumors that developed in VDR-/- mice were classified histologically as sebaceous, squamous or follicular papillomas. Other types of lesions, including basal cell carcinoma, hemangioma and melanotic foci, were occasionally observed in VDR-/- mice (but not in VDR+/+ mice) exposed to DMBA. Quantification of epidermal thickness and BrdU incorporation indicated that skin from VDR-/- mice exhibited hyperproliferation beginning at 7 weeks of age, which was exacerbated by DMBA treatment. Untreated aging VDR-/- mice did not exhibit tumor formation, but did develop a progressive skin phenotype characterized by thickened wrinkled skin, dermoid cysts and long curly nails. Together with previous reports that 1,25D3 inhibits papilloma formation induced by topical DMBA-TPA regimens, our observation of enhanced sensitivity of VDR-/- mice to chemically induced skin carcinogenesis offers compelling evidence that disruption of VDR signaling predisposes to neoplasia.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. I. Ellison, R. L. Eckert, and P. N. MacDonald Evidence for 1,25-Dihydroxyvitamin D3-independent Transactivation by the Vitamin D Receptor: UNCOUPLING THE RECEPTOR AND LIGAND IN KERATINOCYTES J. Biol. Chem., April 13, 2007; 282(15): 10953 - 10962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagpal, S. Na, and R. Rathnachalam Noncalcemic Actions of Vitamin D Receptor Ligands Endocr. Rev., August 1, 2005; 26(5): 662 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakagawa, A. Kawaura, S. Kato, E. Takeda, and T. Okano 1{alpha},25-Dihydroxyvitamin D3 is a preventive factor in the metastasis of lung cancer Carcinogenesis, February 1, 2005; 26(2): 429 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Welsh Vitamin D and breast cancer: insights from animal models Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1721S - 1724S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Zinser and J. Welsh Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice Carcinogenesis, December 1, 2004; 25(12): 2361 - 2372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Bikle Vitamin D and Skin Cancer J. Nutr., December 1, 2004; 134(12): 3472S - 3478S. [Abstract] [Full Text] [PDF]
|
|